<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712296</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 04-0206</org_study_id>
    <secondary_id>P01AT002647-02</secondary_id>
    <nct_id>NCT00712296</nct_id>
  </id_info>
  <brief_title>Effectiveness of Chinese Herbal Therapy for Asthma</brief_title>
  <official_title>Center for Chinese Herbal Therapy for Asthma. Project #2-Clinical Effect of a Chinese Herbal Therapy in Human Asthma-Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of an anti-asthma herbal medicine&#xD;
      intervention (ASHMI) in adult asthmatics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a major public health problem worldwide, particularly in westernized societies and&#xD;
      has continued to increase in prevalence over the past two decades. Inhaled corticosteroids&#xD;
      have become the first-line treatment for persistent asthma even though side effects have been&#xD;
      reported. New asthma medications, including leukotriene inhibitors and anti-IgE, have shown&#xD;
      limited benefits. Patients have increasingly turned to complementary and alternative medicine&#xD;
      (CAM) for treatment of their asthma, despite the uncertainty of its benefits due a lack of&#xD;
      well-controlled scientific studies.&#xD;
&#xD;
      We have developed a Chinese herbal formula composed of 3 herbs called ASHMI. It has been&#xD;
      previously shown in murine studies that ASHMI (a formula containing Ling Zhi, Ku Shen and Gan&#xD;
      Cao) has therapeutic effects on the major pathogenic mechanisms of asthma-airway&#xD;
      hyperreactivity, pulmonary inflammation, and airway remodeling, as well as a down-regulating&#xD;
      of TH2 response. A subsequent study in 91 asthmatic patients in Weifang, China found ASHMI to&#xD;
      be a safe and effective alternative to prednisone for treating asthma and exhibited a&#xD;
      beneficial effect on TH1 and TH2 balance. Additionally, a Phase I study conducted in the&#xD;
      United States showed good tolerability to ASHMI. Based on these preliminary studies, we&#xD;
      hypothesize that ASHMI will be a safe medication in patients with asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">August 2008</start_date>
  <completion_date type="Actual">September 29, 2009</completion_date>
  <primary_completion_date type="Actual">September 29, 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose, Urea and Creatinine Phase I</measure>
    <time_frame>1 week after receiving active drug or placebo</time_frame>
    <description>Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL) and Creatinine(mg/dL) in subjects enrolled in Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sodium, Potassium, Chloride and CO2 Phase I</measure>
    <time_frame>1 week after receiving active drug or placebo</time_frame>
    <description>Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and CO2 (meq/L) in subjects enrolled in Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase I</measure>
    <time_frame>1 week after receiving active drug and placebo</time_frame>
    <description>Summary of Laboratory data for Serum glutamic pyruvic transaminase and Serum glutamic oxaloacetic transaminase in subjects enrolled in Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Results for White Blood Cell, Hemoglobin and Platelet in Phase I</measure>
    <time_frame>1 week after receiving active drug and placebo</time_frame>
    <description>Summary of Laboratory data for White Blood Cell(cells*10^3/uL), Hemoglobin(cells*10^3/uL) and Platelet(cells*10^3/uL)in subjects enrolled in Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin Laboratory Results in Phase I</measure>
    <time_frame>1 week</time_frame>
    <description>Summary of hemoglobin as Outcome measures included laboratory data for subjects enrolled in Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Results for Glucose, Urea, Creatinine, Bilirubin Total and Bilirubin Direct Phase II Study</measure>
    <time_frame>28 weeks</time_frame>
    <description>Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL), Creatinine(mg/dL), Bilirubin Total(mg/dL) and Bilirubin Direct(mg/dL)in subjects in Phase II&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Results for Sodium,Potassium, Chloride and Bicarbonate in Phase II Study</measure>
    <time_frame>28 weeks</time_frame>
    <description>Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and Bicarbonate(meq/L)in subjects in Phase II&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Results for Alkaline Phosphatase,Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase II Study</measure>
    <time_frame>28 weeks</time_frame>
    <description>Summary of Laboratory data for Alkaline phosphatase(IU/L),Serum glutamic pyruvic transaminase(IU/L)and Serum glutamic oxaloacetic transaminase(IU/L) in subjects in Phase II study&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Results for White Blood Cell Count and Platelet in Subjects in Phase II Study</measure>
    <time_frame>28 weeks</time_frame>
    <description>Summary of Laboratory data for White Blood Cell Count(cells*10^3/uL) and Platelet (cells*10^3/uL)in Phase II study&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Results for Hemoglobin in Subjects in Phase II Study</measure>
    <time_frame>28 weeks</time_frame>
    <description>Summary of Laboratory data for hemoglobin(g/dL)in subjects in Phase II study.&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>ASHMI 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASHMI 4 capsules twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASHMI 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASHMI 12 capsules twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 6 capsules twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASHMI 4</intervention_name>
    <description>4 capsules orally twice a day</description>
    <arm_group_label>ASHMI 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASHMI 12</intervention_name>
    <description>12 capsules orally twice a day</description>
    <arm_group_label>ASHMI 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 6 capsules twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects ages 18 through 55 and otherwise in good health as determined&#xD;
             by medical history and physical examination&#xD;
&#xD;
          -  History of asthma documented by a physician for at least 6 months&#xD;
&#xD;
          -  Females of childbearing potential must be sexually inactive or take effective birth&#xD;
             control measures, as deemed appropriate by the investigator, for the duration of the&#xD;
             study&#xD;
&#xD;
          -  The subject agrees to participate in the study&#xD;
&#xD;
          -  Subjects must have one of the following:&#xD;
&#xD;
          -  one asthma-related unscheduled visit to an Emergency Department or clinic in the past&#xD;
             12 months&#xD;
&#xD;
          -  One overnight hospitalization in the past 12 months&#xD;
&#xD;
          -  Disturbed sleep more than twice in the past month&#xD;
&#xD;
          -  Asthma symptoms ≥8 times in the past month&#xD;
&#xD;
          -  use of a β2-agonist ≥8 times in the past month&#xD;
&#xD;
          -  two short courses (3-7 days) of oral corticosteroids in the last 12 months&#xD;
&#xD;
          -  FEV1 &lt;80% predicted AND Use of inhaled corticosteroid (ICS) for at least 1 month prior&#xD;
             to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute illness (such as cold, flu, etc.) within two weeks before the screening visit&#xD;
&#xD;
          -  Any history of systemic disease that in the investigator's opinion would preclude the&#xD;
             subject from participating in this study, including hepatitis virus infection&#xD;
&#xD;
          -  History of chronic obstructive lung disease, emphysema, or other chronic respiratory&#xD;
             condition&#xD;
&#xD;
          -  Abnormal hepatic function (ALT/AST and bilirubin &gt;1.25 x upper limit of normal)&#xD;
&#xD;
          -  Abnormal bone marrow function (WBC &lt;4 x 103/mm3; platelets &lt;100 x 103/mm3; Hgb &lt;11&#xD;
             g/dl)&#xD;
&#xD;
          -  Abnormal renal function (BUN and creatinine &gt;1.25 x upper limit of normal)&#xD;
&#xD;
          -  Clinically significant abnormal electrocardiogram&#xD;
&#xD;
          -  FEV1 &lt;50% predicted&#xD;
&#xD;
          -  Participation in another experimental therapy study within 30 days of this study&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Pregnant or lactating female subjects. Females of childbearing potential will need a&#xD;
             negative serum pregnancy test at screening to be considered for this study&#xD;
&#xD;
          -  Subjects receiving treatment with Omalizumab or immunotherapy for asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan P Wisnivesky, MD, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wen MC, Wei CH, Hu ZQ, Srivastava K, Ko J, Xi ST, Mu DZ, Du JB, Li GH, Wallenstein S, Sampson H, Kattan M, Li XM. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J Allergy Clin Immunol. 2005 Sep;116(3):517-24.</citation>
    <PMID>16159618</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <results_first_submitted>September 22, 2011</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Xiu-Min Li</investigator_full_name>
    <investigator_title>Professor, Pediatrics, Allergy and Immunology</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>alternative medicine</keyword>
  <keyword>complementary medicine</keyword>
  <keyword>herbal therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 10/5/2006-3/12/2010&#xD;
Location: Mount Sinai School of Medicine, New York, NY&#xD;
Phase I Participants Screened 55 Consented 35 Excluded 13 Withdrawn 2&#xD;
Phase II Participants Screened 183 Consented 76 Excluded 19 Screen failed 11</recruitment_details>
      <pre_assignment_details>Phase I: Time frame 1 week; Phase II: Time frame 28 weeks. Participants from Phase I were invited to participate in Phase II and were re-randomized to all three arms of Phase II.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active, Phase I</title>
          <description>Patients received 3 daily doses in which 2, 4 or 6 ASHMI capsules were administered twice a day for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Phase I</title>
          <description>Patients received placebo. (phase I)</description>
        </group>
        <group group_id="P3">
          <title>Active Phase II (ASHMI 4 Caps)</title>
          <description>Patients received active drug. 4 caps twice a day.</description>
        </group>
        <group group_id="P4">
          <title>Active, Phase II (ASHMI 12 Caps )</title>
          <description>Patients received active drug. 12 caps twice a day.</description>
        </group>
        <group group_id="P5">
          <title>Placebo, Phase II</title>
          <description>Patients received placebo. (phase II)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I ( 1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II (28 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2">ASHMI/Placebo was discontinued on 9/29/10.20 participants were re-randomized into the Phase II.</participants>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ASHMI/Placebo was discontinued on 9/29/10. 20 participants were re-randomized into the Phase II.</population>
      <group_list>
        <group group_id="B1">
          <title>Active, Phase I</title>
          <description>Patients received 3 daily doses in which 2, 4, or 6 ASHMI capsules were administered twice a day for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Phase I</title>
          <description>Patients received placebo.</description>
        </group>
        <group group_id="B3">
          <title>Active, Phase II (ASHMI 4 Caps )</title>
          <description>Patients received active drug, 4 caps twice a day</description>
        </group>
        <group group_id="B4">
          <title>Active, Phase II (ASHMI 12 Caps)</title>
          <description>Patients received active drug, 12 caps twice a day</description>
        </group>
        <group group_id="B5">
          <title>Placebo, Phase II</title>
          <description>Patients received placebo.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="15"/>
            <count group_id="B6" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>ASHMI/Placebo was discontinued on 9/29/10.20 participants were re-randomized into the Phase II.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Phase 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="7"/>
                    <measurement group_id="B2" value="31" spread="9"/>
                    <measurement group_id="B6" value="31.6" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="16"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="44" spread="10"/>
                    <measurement group_id="B4" value="44" spread="8"/>
                    <measurement group_id="B5" value="40" spread="10"/>
                    <measurement group_id="B6" value="42.7" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>This includes the number of males and females for the randomized study population for Phase I and Phase II</description>
          <population>ASHMI/Placebo was discontinued on 9/29/10.20 participants were re-randomized into the Phase II.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Phase 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="16"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>ASHMI/Placebo was discontinued on 9/29/10. 20 participants were re-randomized into the Phase II.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Phase 1, White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1, Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1, Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1, Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1, Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2, White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="16"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2, Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="16"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2, Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="16"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2, Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="16"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2, Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="16"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose, Urea and Creatinine Phase I</title>
        <description>Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL) and Creatinine(mg/dL) in subjects enrolled in Phase 1</description>
        <time_frame>1 week after receiving active drug or placebo</time_frame>
        <population>For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Phase I Baseline</title>
            <description>Baseline results for patients on ASHMI.</description>
          </group>
          <group group_id="O2">
            <title>Active Phase I Post Treatment</title>
            <description>Post Treatment results after 1 week for patients on ASHMI.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Phase I Baseline</title>
            <description>Baseline results for participants who received placebo.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase I Post Treatment</title>
            <description>Post Treatment results for participants who received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose, Urea and Creatinine Phase I</title>
          <description>Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL) and Creatinine(mg/dL) in subjects enrolled in Phase 1</description>
          <population>For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="12"/>
                    <measurement group_id="O2" value="79" spread="9"/>
                    <measurement group_id="O3" value="75" spread="14"/>
                    <measurement group_id="O4" value="71" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="3"/>
                    <measurement group_id="O2" value="13" spread="3"/>
                    <measurement group_id="O3" value="16" spread="4"/>
                    <measurement group_id="O4" value="17" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.2"/>
                    <measurement group_id="O3" value="0.9" spread="0.1"/>
                    <measurement group_id="O4" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sodium, Potassium, Chloride and CO2 Phase I</title>
        <description>Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and CO2 (meq/L) in subjects enrolled in Phase 1</description>
        <time_frame>1 week after receiving active drug or placebo</time_frame>
        <population>For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Phase I Baseline</title>
            <description>Baseline results for patients on ASHMI.</description>
          </group>
          <group group_id="O2">
            <title>Active Phase I Post Treatment</title>
            <description>Post Treatment results after 1 week for patients on ASHMI.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Phase I Baseline</title>
            <description>Baseline results for participants who received placebo.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase I Post Treatment</title>
            <description>Post Treatment results for participants who received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium, Potassium, Chloride and CO2 Phase I</title>
          <description>Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and CO2 (meq/L) in subjects enrolled in Phase 1</description>
          <population>For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
          <units>meq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium (meq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" spread="2"/>
                    <measurement group_id="O2" value="140" spread="2"/>
                    <measurement group_id="O3" value="139" spread="3"/>
                    <measurement group_id="O4" value="139" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (meq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="0.3"/>
                    <measurement group_id="O2" value="4" spread="0.4"/>
                    <measurement group_id="O3" value="4" spread="0.4"/>
                    <measurement group_id="O4" value="4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride (meq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" spread="2"/>
                    <measurement group_id="O2" value="103" spread="1"/>
                    <measurement group_id="O3" value="102" spread="1"/>
                    <measurement group_id="O4" value="102" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbon dioxide (meq/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="3"/>
                    <measurement group_id="O2" value="23" spread="2"/>
                    <measurement group_id="O3" value="24" spread="2"/>
                    <measurement group_id="O4" value="24" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase I</title>
        <description>Summary of Laboratory data for Serum glutamic pyruvic transaminase and Serum glutamic oxaloacetic transaminase in subjects enrolled in Phase 1</description>
        <time_frame>1 week after receiving active drug and placebo</time_frame>
        <population>For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Phase I Baseline</title>
            <description>Baseline results for patients on ASHMI.</description>
          </group>
          <group group_id="O2">
            <title>Active Phase I Post Treatment</title>
            <description>Post Treatment results after 1 week for patients on ASHMI.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Phase I Baseline</title>
            <description>Baseline results for participants who received placebo.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase I Post Treatment</title>
            <description>Post Treatment results for participants who received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase I</title>
          <description>Summary of Laboratory data for Serum glutamic pyruvic transaminase and Serum glutamic oxaloacetic transaminase in subjects enrolled in Phase 1</description>
          <population>For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum glutamic pyruvic transaminase (SGPT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="8"/>
                    <measurement group_id="O2" value="20" spread="8"/>
                    <measurement group_id="O3" value="21" spread="9"/>
                    <measurement group_id="O4" value="20" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum glutamic oxaloacetic transaminase (SGOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="4"/>
                    <measurement group_id="O2" value="20" spread="7"/>
                    <measurement group_id="O3" value="24" spread="8"/>
                    <measurement group_id="O4" value="24" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Laboratory Results for White Blood Cell, Hemoglobin and Platelet in Phase I</title>
        <description>Summary of Laboratory data for White Blood Cell(cells*10^3/uL), Hemoglobin(cells*10^3/uL) and Platelet(cells*10^3/uL)in subjects enrolled in Phase 1</description>
        <time_frame>1 week after receiving active drug and placebo</time_frame>
        <population>For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Phase I Baseline</title>
            <description>Baseline results for patients on ASHMI.</description>
          </group>
          <group group_id="O2">
            <title>Active Phase I Post Treatment</title>
            <description>Post Treatment results after 1 week for patients on ASHMI.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Phase I Baseline</title>
            <description>Baseline results for participants who received placebo.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase I Post Treatment</title>
            <description>Post Treatment results for participants who received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Results for White Blood Cell, Hemoglobin and Platelet in Phase I</title>
          <description>Summary of Laboratory data for White Blood Cell(cells*10^3/uL), Hemoglobin(cells*10^3/uL) and Platelet(cells*10^3/uL)in subjects enrolled in Phase 1</description>
          <population>For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
          <units>cells*10^3/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>White Blood Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="2"/>
                    <measurement group_id="O2" value="7" spread="1"/>
                    <measurement group_id="O3" value="7" spread="2"/>
                    <measurement group_id="O4" value="7" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292" spread="81"/>
                    <measurement group_id="O2" value="238" spread="123"/>
                    <measurement group_id="O3" value="281" spread="60"/>
                    <measurement group_id="O4" value="273" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin Laboratory Results in Phase I</title>
        <description>Summary of hemoglobin as Outcome measures included laboratory data for subjects enrolled in Phase 1</description>
        <time_frame>1 week</time_frame>
        <population>For the Phase I study descriptive statistics were used to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Phase I Baseline</title>
            <description>Baseline results for patients on ASHMI.</description>
          </group>
          <group group_id="O2">
            <title>Active Phase I Post Treatment</title>
            <description>Post Treatment results after 1 week for patients on ASHMI.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Phase I Baseline</title>
            <description>Baseline results for participants who received placebo.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase I Post Treatment</title>
            <description>Post Treatment results for participants who received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Laboratory Results in Phase I</title>
          <description>Summary of hemoglobin as Outcome measures included laboratory data for subjects enrolled in Phase 1</description>
          <population>For the Phase I study descriptive statistics were used to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="0.9"/>
                    <measurement group_id="O2" value="13" spread="1"/>
                    <measurement group_id="O3" value="14" spread="2"/>
                    <measurement group_id="O4" value="14" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Laboratory Results for Glucose, Urea, Creatinine, Bilirubin Total and Bilirubin Direct Phase II Study</title>
        <description>Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL), Creatinine(mg/dL), Bilirubin Total(mg/dL) and Bilirubin Direct(mg/dL)in subjects in Phase II&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
        <time_frame>28 weeks</time_frame>
        <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 29, 2009, the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Phase II Baseline</title>
            <description>Patients received placebo. at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Active Phase II (ASHMI 4 Caps) Baseline</title>
            <description>Patients received active drug. 4 caps twice a day. at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Active Phase II (ASHMI 12 Caps) Baseline</title>
            <description>Patients received active drug. 12 caps twice a day. at baseline.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II Visit 5</title>
            <description>Patients received placebo. at visit 5.</description>
          </group>
          <group group_id="O5">
            <title>Active Phase II (ASHMI 4 Caps) Visit 5</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O6">
            <title>Active Phase II (ASHMI 12 Caps) Visit 5</title>
            <description>Patients received active drug. 12 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Phase II Visit 10</title>
            <description>Patients received placebo. at visit 10.</description>
          </group>
          <group group_id="O8">
            <title>Active Phase II (ASHMI 4 Caps) Visit 10</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 10.</description>
          </group>
          <group group_id="O9">
            <title>Active Phase II (ASHMI 12 Caps) Visit 10</title>
            <description>Patients received active drug. 12 caps twice a day. at visit 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Results for Glucose, Urea, Creatinine, Bilirubin Total and Bilirubin Direct Phase II Study</title>
          <description>Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL), Creatinine(mg/dL), Bilirubin Total(mg/dL) and Bilirubin Direct(mg/dL)in subjects in Phase II&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
          <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 29, 2009, the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="28.4"/>
                    <measurement group_id="O2" value="79.1" spread="12.1"/>
                    <measurement group_id="O3" value="77.1" spread="12.8"/>
                    <measurement group_id="O4" value="99.9" spread="45.9"/>
                    <measurement group_id="O5" value="77.6" spread="8.8"/>
                    <measurement group_id="O6" value="72.5" spread="12.6"/>
                    <measurement group_id="O7" value="92.0" spread="12.0"/>
                    <measurement group_id="O8" value="95.0" spread="38.2"/>
                    <measurement group_id="O9" value="101.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="4.1"/>
                    <measurement group_id="O2" value="13.3" spread="5.4"/>
                    <measurement group_id="O3" value="14.1" spread="5.4"/>
                    <measurement group_id="O4" value="13.9" spread="2.6"/>
                    <measurement group_id="O5" value="13.3" spread="2.5"/>
                    <measurement group_id="O6" value="14.2" spread="4.2"/>
                    <measurement group_id="O7" value="15.0" spread="2.6"/>
                    <measurement group_id="O8" value="15.0" spread="8.5"/>
                    <measurement group_id="O9" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.2"/>
                    <measurement group_id="O3" value="0.8" spread="0.1"/>
                    <measurement group_id="O4" value="0.8" spread="0.1"/>
                    <measurement group_id="O5" value="0.9" spread="0.3"/>
                    <measurement group_id="O6" value="0.9" spread="0.2"/>
                    <measurement group_id="O7" value="1.0" spread="0.1"/>
                    <measurement group_id="O8" value="0.9" spread="0.1"/>
                    <measurement group_id="O9" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.2"/>
                    <measurement group_id="O2" value="0.4" spread="0.2"/>
                    <measurement group_id="O3" value="0.4" spread="0.2"/>
                    <measurement group_id="O4" value="0.5" spread="0.2"/>
                    <measurement group_id="O5" value="0.4" spread="0.2"/>
                    <measurement group_id="O6" value="0.3" spread="0.1"/>
                    <measurement group_id="O7" value="0.4" spread="0.2"/>
                    <measurement group_id="O8" value="0.4" spread="0.2"/>
                    <measurement group_id="O9" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Direct</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.0"/>
                    <measurement group_id="O2" value="0.1" spread="0.0"/>
                    <measurement group_id="O3" value="0.1" spread="0.0"/>
                    <measurement group_id="O4" value="0.1" spread="0.0"/>
                    <measurement group_id="O5" value="0.1" spread="0.0"/>
                    <measurement group_id="O6" value="0.1" spread="0.0"/>
                    <measurement group_id="O7" value="0.1" spread="0.1"/>
                    <measurement group_id="O8" value="0.1" spread="0.0"/>
                    <measurement group_id="O9" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Laboratory Results for Sodium,Potassium, Chloride and Bicarbonate in Phase II Study</title>
        <description>Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and Bicarbonate(meq/L)in subjects in Phase II&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
        <time_frame>28 weeks</time_frame>
        <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Phase II Baseline</title>
            <description>Patients received placebo at baseline</description>
          </group>
          <group group_id="O2">
            <title>Active Phase II (ASHMI 4 Caps ) Baseline</title>
            <description>Patients received active drug. 4 caps twice a day at baseline</description>
          </group>
          <group group_id="O3">
            <title>Active Phase II (ASHMI 12 Caps) Baseline</title>
            <description>Patients received active drug. 12 caps twice a day. Baseline</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II Visit 5</title>
            <description>Patients received placebo. at visit 5.</description>
          </group>
          <group group_id="O5">
            <title>Active Phase II (ASHMI 4 Caps) Visit 5</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O6">
            <title>Active Phase II (ASHMI 12 Caps) Visit 5</title>
            <description>Patients received active drug. 12 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Phase II Visit 10</title>
            <description>Patients received placebo. at visit 10.</description>
          </group>
          <group group_id="O8">
            <title>Active Phase II (ASHMI 4 Caps) Visit 10</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 10.</description>
          </group>
          <group group_id="O9">
            <title>Active Phase II (ASHMI 12 Caps) Visit 10</title>
            <description>Patients received active drug. 12 caps a day. at visit 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Results for Sodium,Potassium, Chloride and Bicarbonate in Phase II Study</title>
          <description>Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and Bicarbonate(meq/L)in subjects in Phase II&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
          <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed.</population>
          <units>meq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.6" spread="1.6"/>
                    <measurement group_id="O2" value="140.3" spread="1.9"/>
                    <measurement group_id="O3" value="140.5" spread="2.3"/>
                    <measurement group_id="O4" value="139.5" spread="2.1"/>
                    <measurement group_id="O5" value="140.1" spread="2.2"/>
                    <measurement group_id="O6" value="139.6" spread="2.5"/>
                    <measurement group_id="O7" value="139.7" spread="1.5"/>
                    <measurement group_id="O8" value="140" spread="1.4"/>
                    <measurement group_id="O9" value="140.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.4"/>
                    <measurement group_id="O2" value="4.1" spread="0.2"/>
                    <measurement group_id="O3" value="4.1" spread="0.3"/>
                    <measurement group_id="O4" value="4.1" spread="0.3"/>
                    <measurement group_id="O5" value="4.1" spread="0.1"/>
                    <measurement group_id="O6" value="4.1" spread="0.3"/>
                    <measurement group_id="O7" value="4.2" spread="0.6"/>
                    <measurement group_id="O8" value="4.1" spread="0.5"/>
                    <measurement group_id="O9" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.5" spread="2.2"/>
                    <measurement group_id="O2" value="102.6" spread="1.9"/>
                    <measurement group_id="O3" value="102.6" spread="2.5"/>
                    <measurement group_id="O4" value="102.4" spread="2.2"/>
                    <measurement group_id="O5" value="102.9" spread="3.2"/>
                    <measurement group_id="O6" value="102.3" spread="3.5"/>
                    <measurement group_id="O7" value="102.3" spread="0.6"/>
                    <measurement group_id="O8" value="101.5" spread="2.1"/>
                    <measurement group_id="O9" value="108.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="2.7"/>
                    <measurement group_id="O2" value="26.7" spread="2.5"/>
                    <measurement group_id="O3" value="27.5" spread="1.6"/>
                    <measurement group_id="O4" value="25.8" spread="2.4"/>
                    <measurement group_id="O5" value="26.2" spread="2.0"/>
                    <measurement group_id="O6" value="26.2" spread="1.7"/>
                    <measurement group_id="O7" value="27.1" spread="1.6"/>
                    <measurement group_id="O8" value="26.3" spread="2.9"/>
                    <measurement group_id="O9" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Laboratory Results for Alkaline Phosphatase,Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase II Study</title>
        <description>Summary of Laboratory data for Alkaline phosphatase(IU/L),Serum glutamic pyruvic transaminase(IU/L)and Serum glutamic oxaloacetic transaminase(IU/L) in subjects in Phase II study&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
        <time_frame>28 weeks</time_frame>
        <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 28, 2009, the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Phase II Baseline</title>
            <description>Patients received placebo. at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Active Phase II (ASHMI 4 Caps) Baseline</title>
            <description>Patients received active drug. 4 caps twice a day. at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Active Phase II (ASHMI 12 Caps) Baseline</title>
            <description>Patients received active drug. 12 caps twice a day. at baseline.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II Visit 5</title>
            <description>Patients received placebo. at visit 5.</description>
          </group>
          <group group_id="O5">
            <title>Active Phase II (ASHMI 4 Caps) Visit 5</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O6">
            <title>Active Phase II (ASHMI 12 Caps) Visit 5</title>
            <description>Patients received active drug. 12 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Phase II Visit 10</title>
            <description>Patients received placebo. at visit 10.</description>
          </group>
          <group group_id="O8">
            <title>Active Phase II (ASHMI 4 Caps) Visit 10</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 10.</description>
          </group>
          <group group_id="O9">
            <title>Active Phase II (ASHMI 12 Caps) Visit 10</title>
            <description>Patients received active drug. 12 caps twice a day. at visit 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Results for Alkaline Phosphatase,Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase II Study</title>
          <description>Summary of Laboratory data for Alkaline phosphatase(IU/L),Serum glutamic pyruvic transaminase(IU/L)and Serum glutamic oxaloacetic transaminase(IU/L) in subjects in Phase II study&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
          <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 28, 2009, the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" spread="22.2"/>
                    <measurement group_id="O2" value="91.3" spread="23.0"/>
                    <measurement group_id="O3" value="76.6" spread="24.7"/>
                    <measurement group_id="O4" value="81.1" spread="24.8"/>
                    <measurement group_id="O5" value="29.7" spread="25.7"/>
                    <measurement group_id="O6" value="83.2" spread="25.0"/>
                    <measurement group_id="O7" value="61.7" spread="18.5"/>
                    <measurement group_id="O8" value="98.0" spread="5.7"/>
                    <measurement group_id="O9" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum glutamic pyruvic transaminase (SGPT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="11.6"/>
                    <measurement group_id="O2" value="21.9" spread="18.2"/>
                    <measurement group_id="O3" value="21.3" spread="9.4"/>
                    <measurement group_id="O4" value="26.9" spread="11.9"/>
                    <measurement group_id="O5" value="22.0" spread="11.0"/>
                    <measurement group_id="O6" value="22.5" spread="8.6"/>
                    <measurement group_id="O7" value="24.3" spread="7.4"/>
                    <measurement group_id="O8" value="14.5" spread="4.9"/>
                    <measurement group_id="O9" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum glutamic oxaloacetic transaminase (SGOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="8.4"/>
                    <measurement group_id="O2" value="22.0" spread="9.3"/>
                    <measurement group_id="O3" value="24.7" spread="7.3"/>
                    <measurement group_id="O4" value="24.8" spread="8.1"/>
                    <measurement group_id="O5" value="25.8" spread="9.6"/>
                    <measurement group_id="O6" value="25.6" spread="8.7"/>
                    <measurement group_id="O7" value="25.3" spread="8.9"/>
                    <measurement group_id="O8" value="21.0" spread="7.1"/>
                    <measurement group_id="O9" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Laboratory Results for White Blood Cell Count and Platelet in Subjects in Phase II Study</title>
        <description>Summary of Laboratory data for White Blood Cell Count(cells*10^3/uL) and Platelet (cells*10^3/uL)in Phase II study&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
        <time_frame>28 weeks</time_frame>
        <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 28, 2009,the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Phase II Baseline</title>
            <description>Patients received placebo. at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Active Phase II (ASHMI 4 Caps) Baseline</title>
            <description>Patients received active drug. 4 caps twice a day. at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Active Phase II (ASHMI 12 Caps) Baseline</title>
            <description>Patients received active drug. 12 caps twice a day. at baseline.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II Visit 5</title>
            <description>Patients received placebo. at visit 5.</description>
          </group>
          <group group_id="O5">
            <title>Active Phase II (ASHMI 4 Caps) Visit 5</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O6">
            <title>Active Phase II (ASHMI 12 Caps) Visit 5</title>
            <description>Patients received active drug. 12 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Phase II Visit 10</title>
            <description>Patients received placebo. at visit 10.</description>
          </group>
          <group group_id="O8">
            <title>Active Phase II (ASHMI 4 Caps) Visit 10</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 10.</description>
          </group>
          <group group_id="O9">
            <title>Active Phase II (ASHMI 12 Caps) Visit 10</title>
            <description>Patients received active drug. 12 caps twice a day. at visit 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Results for White Blood Cell Count and Platelet in Subjects in Phase II Study</title>
          <description>Summary of Laboratory data for White Blood Cell Count(cells*10^3/uL) and Platelet (cells*10^3/uL)in Phase II study&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
          <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 28, 2009,the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).</population>
          <units>cells*10^3/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>White Blood Cell Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="2.3"/>
                    <measurement group_id="O2" value="7.6" spread="2.6"/>
                    <measurement group_id="O3" value="7.2" spread="1.4"/>
                    <measurement group_id="O4" value="6.5" spread="2.1"/>
                    <measurement group_id="O5" value="7.5" spread="2.7"/>
                    <measurement group_id="O6" value="6.8" spread="1.9"/>
                    <measurement group_id="O7" value="7.9" spread="2.7"/>
                    <measurement group_id="O8" value="9.4" spread="0.7"/>
                    <measurement group_id="O9" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.5" spread="74.6"/>
                    <measurement group_id="O2" value="268.2" spread="49.0"/>
                    <measurement group_id="O3" value="267.1" spread="89.5"/>
                    <measurement group_id="O4" value="275.0" spread="86.3"/>
                    <measurement group_id="O5" value="283.3" spread="58.5"/>
                    <measurement group_id="O6" value="275.6" spread="119.6"/>
                    <measurement group_id="O7" value="280.0" spread="133.8"/>
                    <measurement group_id="O8" value="348.5" spread="29.0"/>
                    <measurement group_id="O9" value="269.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Laboratory Results for Hemoglobin in Subjects in Phase II Study</title>
        <description>Summary of Laboratory data for hemoglobin(g/dL)in subjects in Phase II study.&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
        <time_frame>28 weeks</time_frame>
        <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 28, 2009, the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Phase II Baseline</title>
            <description>Patients received placebo. at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Active Phase II (ASHMI 4 Caps) Baseline</title>
            <description>Patients received active drug. 4 caps twice a day. at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Active Phase II (ASHMI 12 Caps) Baseline</title>
            <description>Patients received active drug.12 caps twice a day. at baseline.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II Visit 5</title>
            <description>Patients received placebo. at visit 5.</description>
          </group>
          <group group_id="O5">
            <title>Active Phase II (ASHMI 4 Caps) Visit 5</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O6">
            <title>Active Phase II (ASHMI 12 Caps) Visit 5</title>
            <description>Patients received active drug. 12 caps twice a day. at visit 5.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Phase II Visit 10</title>
            <description>Patients received placebo. at day 10.</description>
          </group>
          <group group_id="O8">
            <title>Active Phase II (ASHMI 4 Caps) Visit 10</title>
            <description>Patients received active drug. 4 caps twice a day. at visit 10.</description>
          </group>
          <group group_id="O9">
            <title>Active Phase II (ASHMI 12 Caps) Visit 10</title>
            <description>Patients received active drug.12 caps twice a day. at visit 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Results for Hemoglobin in Subjects in Phase II Study</title>
          <description>Summary of Laboratory data for hemoglobin(g/dL)in subjects in Phase II study.&#xD;
Limited to Measurements before discontinuation of ASHMI treatment</description>
          <population>The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 28, 2009, the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="1.4"/>
                    <measurement group_id="O2" value="13.5" spread="1.6"/>
                    <measurement group_id="O3" value="12.8" spread="1.2"/>
                    <measurement group_id="O4" value="13.9" spread="1.2"/>
                    <measurement group_id="O5" value="13.7" spread="1.4"/>
                    <measurement group_id="O6" value="12.9" spread="1.5"/>
                    <measurement group_id="O7" value="13.7" spread="1.7"/>
                    <measurement group_id="O8" value="13.9" spread="1.5"/>
                    <measurement group_id="O9" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Phase I: 1 week Phase II: 28 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Phase I (ASHMI 2 Caps Twice a Day)</title>
          <description>Patients received 2, 4, or 6 ASHMI capsules were administered twice daily for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Phase I (2 Caps Twice a Day)</title>
          <description>Patients received placebo. 2 caps twice a day.</description>
        </group>
        <group group_id="E3">
          <title>Active Phase I (ASHMI 4 Caps)</title>
          <description>Patients received active drug. 4 caps twice a day.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Phase I (4 Caps Twice a Day)</title>
          <description>Patients received placebo. 4 caps twice a day.</description>
        </group>
        <group group_id="E5">
          <title>Active Phase I (ASHMI 6 Caps)</title>
          <description>Patients received active drug. 6 caps twice a day.</description>
        </group>
        <group group_id="E6">
          <title>Placebo Phase I</title>
          <description>Patients received placebo.</description>
        </group>
        <group group_id="E7">
          <title>Active Phase II (ASHMI 4 Caps Twice a Day)</title>
          <description>Patients received active drug.Based on revised adverse event criteria on January 2010.</description>
        </group>
        <group group_id="E8">
          <title>Active Phase II (ASHMI 12 Caps)</title>
          <description>Patients received active drug. 12 caps twice a day.</description>
        </group>
        <group group_id="E9">
          <title>Placebo Phase II</title>
          <description>Patients received placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Elevated Liver Enzymes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Body aches and fatigue associated with subject's typical prementrual syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Transient upper extremity itchiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Decreased total serum bicarbonate level</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back muscle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Glucosuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Decreased Glucose Level</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Decreased Hemoglobin Level</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Decreased White Blood Cell Count</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Trichomonas in urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Increased Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Increased Creatine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Emergency room visit for asthma exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Unscheduled physician visit for asthma exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The Phase II study was stopped after 46 subjects were randomized. Since the number of subjects and the follow-up information did not provide adequate power, all statistical analysis plan was changed to descriptive summaries for each group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Xiu-Min Li, MD</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-1755</phone>
      <email>Xiu-min.li@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

